Table 4.

Cognitive and pathological features in each APOE4 or MAPT haplotype

Features	APOE4 + (N = 28)	APOE4 − (N = 90)	P value	MAPT H1/H1 (N = 103)	MAPT H1/H2 (N = 15)	P value
Male, No. (%)	19 (68%)	53 (59%)	0.53	61 (59%)	11 (73%)	0.45
Age at death, years	73 ± 9	74 ± 8	0.66	73 ± 9	74 ± 8	0.66
Cognitive impairment	14 (56%)	74 (80%)	0.002	76 (74%)	12 (80%)	1.00
Overall Test Battery Mean	41 ± 9	41 ± 8	0.89	40 ± 8	44 ± 8	0.24
Braak neurofibrillary tangle stage	III (II, III)	II (II, III)	0.61	II (II, III)	II (II, IV)	0.68
Thal amyloid phase	3 (1, 4)	0 (0, 3)	<0.001	0 (0, 3)	1 (0, 3)	0.71
Alzheimer’s disease	6 (21%)	9 (10%)	1.00	12 (12%)	3 (20%)	1.00
Lewy-related pathology	0 (0%)	8 (9%)	1.00	4 (4%)	4 (27%)	1.00
Total tau burden	7 (6, 7)	7 (4, 8)	0.93	7 (6, 7)	7 (4, 8)	0.93

Values are n (%), mean ± SD, and median (25th, 75th %-tile).